Sinovac Biotech (SVA) Reports Q4 EPS of $0.01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Sinovac Reports Unaudited Fourth Quarter and Full Year 2015 Financial Results
April 5, 2016 6:16 AM EDTBEIJING, April 5, 2016 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited fourth quarter and twelve month financial results for the period ended December 31, 2015.
Fourth Quarter 2015 Financial Highlights(compared to the fourth quarter of 2014)
Quarterly sales from continuing operations were $23.0million, an increase of 13.1% from $20.3 million in the prior year period. Gross profit from continuing operations was $15.7million, an increase of 2.3% from $15.3million in the prior year period. Gross margin was 68.3%, compared to... More